RNS Number: 5536Y

Maven Income and Growth VCT 5 PLC

26 February 2025

### Maven Income and Growth VCT 5 PLC

## Unaudited Net Asset Value and Proposed Final Dividend

## Unaudited Net Asset Value

On 13 December 2024, the Directors of Maven Income and Growth VCT 5 PLC (the Company) announced that the unaudited net asset value of the Company as at 30 November 2024 was 32.39p per Ordinary Share.

## **Proposed Final Dividend**

The Directors understand the importance to Shareholders of regular tax free distributions and, following the completion of several profitable private company exits, elected to improve the dividend policy. From the year to 30 November 2024 onwards, the Company has increased its target annual dividend from 5% to 6% of the NAV per Ordinary Share at the immediately preceding year end. Shareholders should be aware that this remains a target and that decisions on distributions take into consideration a number of factors, including the realisation of capital gains, the adequacy of distributable reserves, the availability of surplus revenue, and the VCT qualifying level, all of which are kept under close and regular review.

The Directors propose that a final dividend of 1.00p per Ordinary Share in respect of the year ended 30 November 2024, be paid on 9 May 2025 to Shareholders on the register at close of business on 28 March 2025. This will bring the annual dividend to 2.00p per Ordinary Share, representing an annual yield of 6.15% based on the NAV at the immediately preceding year end.

Since the Company's launch, and after receipt of the proposed final dividend, a total of 54.00p per Ordinary Share will have been distributed in tax-free dividends. It should be noted that the effect of paying dividends is to reduce the NAV of the Company by the total cost of the distribution.

# **Dividend Investment Scheme**

The Company has in place a Dividend Investment Scheme (DIS) through which Shareholders may elect to have their dividend payments used to apply for new Ordinary Shares issued by the Company under the standing authority requested from Shareholders at Annual General Meetings. Shares issued under the DIS should qualify for VCT tax reliefs applicable for the tax year in which they are allotted. Terms & conditions of the scheme, together with a mandate form, are available from the Company's webpage at: <a href="https://www.mavencp.com/migvet5">www.mavencp.com/migvet5</a>.

Shareholders who have not previously applied to participate in the DIS and who wish to do so in respect of the dividend payable on 9 May 2025, should ensure that a mandate form is received by the Company's Registrars, The City Partnership (UK) Limited, prior to the dividend election date of 11 April 2025. Election to participate in the DIS can also be made through the Registrar's online investor hub at <a href="https://maven-cp.cityhub.uk.com">https://maven-cp.cityhub.uk.com</a>.

Further to the information disclosed above, the Directors confirm that they are satisfied that all inside information (as defined by Article 7 of the Market Abuse Regulation (596/2014/EU)) that the Directors and the Company may have in their possession relating to the Company during the 30 day closed period leading up to the announcement of its annual results for the year ended 30 November 2024 has been or will be notified to a regulatory information service.

Issued on behalf of the Board

Maven Capital Partners UK LLP

Company Secretary

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <a href="mailto:rns@lseg.com">rns@lseg.com</a> or visit <a href="www.ms.com">www.ms.com</a>.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <a href="Privacy Policy">Privacy Policy</a>.

END

**MSCPPUPWPUPAGUQ**